UY31478A1 - Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo - Google Patents

Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo

Info

Publication number
UY31478A1
UY31478A1 UY31478A UY31478A UY31478A1 UY 31478 A1 UY31478 A1 UY 31478A1 UY 31478 A UY31478 A UY 31478A UY 31478 A UY31478 A UY 31478A UY 31478 A1 UY31478 A1 UY 31478A1
Authority
UY
Uruguay
Prior art keywords
ron
macrofago
inhibition
receiver
treatment
Prior art date
Application number
UY31478A
Other languages
English (en)
Inventor
Jennifer O'toole
Daniel Pereira
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31478(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31478A1 publication Critical patent/UY31478A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invencion proporciona anticuerpos o fragmentos del mismo, incluyendo anticuerpos humanos, específicos para el Receptor para la Proteína Estimulante del Macrofago (MSP-R o RON), que inhiben la activacion del RON. También proporciona un método para inhibir el RON, en especial el uso de anticuerpos del RON para tratar enfermedades como el cáncer.
UY31478A 2007-11-21 2008-11-20 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo UY31478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
UY31478A1 true UY31478A1 (es) 2009-07-17

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31478A UY31478A1 (es) 2007-11-21 2008-11-20 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo

Country Status (20)

Country Link
US (2) US7947811B2 (es)
EP (1) EP2222703A2 (es)
JP (1) JP5324593B2 (es)
KR (1) KR101227338B1 (es)
CN (1) CN101868478B (es)
AR (1) AR069393A1 (es)
AU (1) AU2008330089B2 (es)
BR (1) BRPI0820218A2 (es)
CA (1) CA2706583A1 (es)
CL (1) CL2008003449A1 (es)
EA (1) EA018717B1 (es)
IL (1) IL204743A (es)
MX (1) MX2010005651A (es)
NZ (1) NZ584271A (es)
PA (1) PA8804901A1 (es)
PE (1) PE20091713A1 (es)
TW (1) TWI417106B (es)
UA (1) UA99633C2 (es)
UY (1) UY31478A1 (es)
WO (1) WO2009070294A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
MX2010008025A (es) * 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
CN105693861A (zh) * 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
AU2011276285A1 (en) 2010-07-06 2013-01-24 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
US10654916B2 (en) 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
CA2890305A1 (en) * 2012-11-30 2014-06-05 Genentech, Inc. Ron compositions and methods of use thereof
US20140242083A1 (en) * 2013-02-26 2014-08-28 Roche Glycart Ag Anti-mcsp antibodies
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
KR20160014563A (ko) * 2014-07-29 2016-02-11 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
WO2016036172A1 (ko) * 2014-09-03 2016-03-10 씨제이헬스케어 주식회사 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도
CN109923129A (zh) 2016-08-26 2019-06-21 新加坡科技研究局 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途
CN110799211A (zh) 2016-09-08 2020-02-14 美国德州精准药靶有限公司 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
WO2022060906A1 (en) * 2020-09-15 2022-03-24 Duke University Coronavirus antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2180535T3 (es) 1991-02-22 2003-02-16 American Cyanamid Co Identificacion de un nuevo gen de tirosina quinasa receptora humana.
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP2004511430A (ja) 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
AU2001295002B2 (en) 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
SE518548C2 (sv) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorberande alster med förbättrad diskretion
WO2002083074A2 (en) 2001-04-13 2002-10-24 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
EP1423428B2 (en) 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
EP1916001B1 (en) 2002-03-04 2011-05-25 Imclone LLC Human antibodies specific to KDR and uses thereof
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
EP1622942B1 (en) 2003-05-01 2014-11-19 ImClone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1773881A4 (en) * 2004-05-13 2008-08-06 Imclone Systems Inc Inhibition of macrophage-stimulating protein receptor (RON)

Also Published As

Publication number Publication date
CA2706583A1 (en) 2009-06-04
CN101868478B (zh) 2013-11-13
EA018717B1 (ru) 2013-10-30
WO2009070294A3 (en) 2009-08-20
IL204743A (en) 2013-10-31
AU2008330089A1 (en) 2009-06-04
CN101868478A (zh) 2010-10-20
US20090136510A1 (en) 2009-05-28
UA99633C2 (ru) 2012-09-10
US8133489B2 (en) 2012-03-13
AU2008330089B2 (en) 2013-09-05
CL2008003449A1 (es) 2010-02-19
TW200936161A (en) 2009-09-01
AR069393A1 (es) 2010-01-20
EP2222703A2 (en) 2010-09-01
KR20100074293A (ko) 2010-07-01
WO2009070294A2 (en) 2009-06-04
PE20091713A1 (es) 2009-11-13
JP2011504176A (ja) 2011-02-03
BRPI0820218A2 (pt) 2015-06-23
TWI417106B (zh) 2013-12-01
US20110135631A1 (en) 2011-06-09
PA8804901A1 (es) 2009-06-23
EA201070636A1 (ru) 2010-10-29
MX2010005651A (es) 2010-06-11
JP5324593B2 (ja) 2013-10-23
KR101227338B1 (ko) 2013-01-28
US7947811B2 (en) 2011-05-24
NZ584271A (en) 2012-05-25
IL204743A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
DOP2006000052A (es) Alargar el tiempo hasta la progresión de la enfermedad o la supervivencia de los pacientes de cáncer
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
BR112015013127A2 (pt) imunoterapia com agentes de ligação
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
CO6640284A2 (es) Miembros enlazadores para citomegalovirus humano
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
BR112021018456A2 (pt) Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
CO2019003865A2 (es) Proteína terapéutica
BR112016023011A2 (pt) tratamento de câncer gástrico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011